No Carolina / New York / Florida        Ph: 561.316.3330

Checkpoint Surgical Enrolls First Patient in Nerve Regeneration Clinical Study

What To Know

  • “This clinical trial allows us to explore the BEST system in humans and has the potential to improve the function, recovery and quality of life in our patients with devastating nerve injuries.
  • The BEST system is designed to provide electrical stimulation of peripheral nerves to promote nerve regeneration as an adjunct to surgical intervention following nerve injury, with the goal of accelerating and improving patient recovery.

Checkpoint Surgical, Inc., the leader in intraoperative nerve repair stimulation technology, today announced it has enrolled the first patient in its multi-center clinical study of the company’s breakthrough nerve regeneration technology.

The patient was enrolled at The Ohio State University, one of four sites actively enrolling patients in the double-blind, randomized clinical trial. Other participating sites include the Medical College of Wisconsin, Northwestern University, and Walter Reed National Military Medical Center. The study is also funded by a Department of Defense Clinical Trial Award to Dr. Amy Moore at The Ohio State University.

The Checkpoint BEST (Brief Electrical Stimulation Therapy) system received Breakthrough Device designation from the FDA in late 2019. The BEST system is designed to provide electrical stimulation of peripheral nerves to promote nerve regeneration as an adjunct to surgical intervention following nerve injury, with the goal of accelerating and improving patient recovery.

“It is an exciting time in nerve surgery,” said Amy Moore, MD, Chair of the Department of Plastic and Reconstructive Surgery at The Ohio State University Wexner Medical Center. “This clinical trial allows us to explore the BEST system in humans and has the potential to improve the function, recovery and quality of life in our patients with devastating nerve injuries.”

“Enrollment of our first patient marks an important milestone as we work to translate this promising therapy into clinical practice,” said Eric Walker, PhD, Director of Clinical Research at Checkpoint Surgical. “We have a great team of clinical and scientific collaborators that have helped us to reach this point, and we continue to work to advance the science and clinical practice to improve recovery following peripheral nerve injuries.”

Latest

CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Unlocking New Hope: Alzheimer’s Patients Join Amyloid-Targeting Therapy Study

0
The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

0
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

0
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

0
The research, presented at the American Society of Interventional Pain Physicians (ASIPP) Annual Meeting, included a registrational Phase 3 trial and an integrated safety analysis of six clinical studies, as well as a real-world analysis of current treatment options and gaps in the clinical management of patients with newly-diagnosed LDH.

Reports breaking medical device and biotechnololgy news

About
Press Releases
Advertise
Privacy
Cookie Policy

Contact:  561.316.3330

Offices: No. Carolina / New York

© Medical Device News Magazine 2024

By using this website you agree to accept Medical Device News Magazine Privacy Policy